The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

Disclosed are a water-dispersible cannabidiol product and a preparation method therefor. The water-dispersible cannabidiol product comprises a product which can be prepared by means of the following method: adding an organic phase containing cannabidiol into a water phase for emulsification; after an organic solvent in an emulsion has been removed, adding glycosylase for a glycosylation treatment; and conducting drying to prepare the water-dispersible cannabidiol product. The prepared dispersible cannabidiol product can be quickly dispersed and dissolved in an aqueous solution. The product after the glycosylation treatment is a glucoside mixture in which cannabidiol is a parent nucleus structure and in which different sugar chain structures have been introduced to phenolic hydroxyl groups.

A new type of biomaterial that can be generated from pollen, methods for its production, the various uses thereof in, for example, biological, medicinal, cosmetic, nutritional and printing applications and the materials/devices that comprise this new material are provided. The biomaterial comprises microgels of sporoderm polymer complex microcapsules (SPC-MCs), produced by deproteinizing the pollen from eudicot plants, in particular of genus Baccharis, Helianthus or Camellia, by contacting it with an aqueous base solution at elevated temperatures for up to 10 hours to obtain porous SPC-MCs, and hydrolytically degrading the SPC-MCs by contacting it with an aqueous base solution for periods up to 60 days to obtain microgels of SPC-MCs.

Nutraceuticals Composition A (metabolic capacity enhancing compositions) comprises extraction or powder from White Kidney Bean, Green Tea, Green Coffee Bean, Garcinia Cambogia, Gymnema Sylvestre, L-Carnitine, Guarana, Ginger Root, Dandelion Root, Capsicum Cayenne, Licorice Root, Ascorbic Acid, d-Calcium Pantothenate, Pyridoxine HCl, Potassium Chloride, Magnesium Carbonate, and Chromium Yeast. Nutraceuticals Composition B (immunity capacity enhancing compositions) comprises extraction or powder from Grape Seed, Ginseng, Garlic, Rosehips, Green tea (Decaf), Astragalus, Beta Glucan Yeast, Reishi, Shitake, Maitake, Agricus blazei, Turkey Tail, Cordyceps, and Coenzyme CoQ10. The methods to make a synergistic Composition A and Composition B are formulated and are capable to provide a bioavailable dietary supplement and phytonutrients that can help modulate metabolism and enhance the human immune system. The supplementation, consumption, of these nutraceutical formulas have preventive and therapeutic roles for chronic diseases, and thus provide anti-aging effects.

The present invention relates to a process in a fluid-bed system for preparing solid formulations having high dispersibility in a cold liquid (room temperature 20° C.-25° C.±2° C.), preferably in water or in a water-based liquid, wherein said solid formulations comprise at least one hydrophobic compound. Furthermore, the present invention relates to said solid formulations obtained by means of said process and to the use thereof for the preparation of dietary supplements, foods for specialist medical purposes (in short FSMPs), pharmaceutical compositions, medical device compositions and/or cosmetic compositions.

The present invention relates to the field of fullerene application, and in particular to an application of fullerene and a derivative thereof in regulating intestinal flora. The fullerene and the derivative thereof may increase beneficial bacteria, decrease harmful bacteria and increase the abundance of intestinal flora when used for regulating intestinal flora, which is thus capable of relieving or treating human diseases (including gastrointestinal diseases, neurodegenerative diseases, metabolic diseases, sleep disorders, inflammation, tumors) and enhancing human immunity, improving animal physiques, regulating animal intestinal tracts, preventing or treating animal diseases, or promoting animal growth with great application prospect.

The subject invention relates to compositions of a polyphenolic Polymer and methods useful for the delivery of substantially water-insoluble drugs and agrochemicals, like Artemisinin, Aspirin, and Pyrethrin. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary polyphenolic partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary polyphenol molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable. More important the whole process and material used is GRAS approved and environmentally safe.

The present invention relates to a pharmaceutical composition for preventing or treating NK/T-cell lymphoma, comprising a phosphodiesterase type 5 inhibitor, the pharmaceutical composition being for inhibiting the reactivation of the Epstein-Barr virus (EBV) induced by a HDAC inhibitor; an anticancer therapy adjuvant composition; and a health functional food. By using the pharmaceutical composition for preventing, alleviating or treating NK/T-cell lymphoma, according to the present invention, EBV reactivation, induced by a HDAC inhibitor used as an anticancer agent for NK/T-cell lymphoma, may be inhibited, and thus side-effects of the HDAC inhibitor may be reduced, and an anticancer effect may be notably increased. Thus, the present invention may be widely used in the pharmaceutical industry on the basis of said effects.

Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.

A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.